Curatis Holding AG (XSWX:CURN) 3-Year RORE % : -98.80% (As of Dec. 2025)


XSWX:CURN Curatis Holding AG XSWX:CURN
33 GF Score
Price CHF23.60
! 7 Warning Signs
View Full Analysis

What is Curatis Holding AG 3-Year RORE %?

Curatis Holding AG XSWX:CURN +3.51% 33 3-Year RORE % is -98.80 as of Dec. 2025. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 7 warning signs investors should review. Among 936 Drug Manufacturers companies, Curatis Holding AG ranks worse than 90.71% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Curatis Holding AG's 3-Year RORE % for the quarter that ended in Dec. 2025 was -98.80%.

The industry rank for Curatis Holding AG's 3-Year RORE % or its related term are showing as below:

XSWX:CURN's 3-Year RORE % is ranked worse than
90.71% of 936 companies
in the Drug Manufacturers industry
Industry Median: 3.075 vs XSWX:CURN: -98.80

Curatis Holding AG  (XSWX:CURN) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Curatis Holding AG 3-Year RORE % Related Terms


Curatis Holding AG 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Curatis Holding AG's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curatis Holding AG 3-Year RORE % Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
0.00 0.00 53.34 -44.01 -98.80

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.34 49.63 -44.01 -45.94 -98.80

XSWX:CURN vs ZTS, UTHR, VTRS: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curatis Holding AG 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Curatis Holding AG's 3-Year RORE % falls into.


XSWX:CURN
33GF Score
Curatis Holding AG XSWX:CURN
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curatis Holding AG 3-Year RORE % Calculation

Curatis Holding AG's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.284--170.122 )/( -171.899-0 )
=169.838/-171.899
=-98.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -98.80 mean?
Curatis Holding AG (XSWX:CURN) has a 3-Year RORE % of -98.80 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Curatis Holding AG and its competitors. According to the industry distribution chart, Curatis Holding AG ranks #849 out of 936 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Curatis Holding AG's 3-Year RORE % too high?
Curatis Holding AG's current 3-Year RORE % is -98.80. Based on the distribution chart, Curatis Holding AG ranks #849 out of 936 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #849 out of 936 companies for 3-Year RORE %. This places Curatis Holding AG in the lower half of its industry. The industry median 3-Year RORE % is 3.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Curatis Holding AG and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current 3-Year RORE % is -98.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current 3-Year RORE % of -98.80. The current 3-Year RORE % is -98.80. Curatis Holding AG's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current 3-Year RORE % is -98.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curatis Holding AG Business Description

Other Exchanges CURNz:UK0QNS:UK26U:Germany
Address Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score

Get the complete analysis for XSWX:CURN

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF23.60
Price